Literature DB >> 15067334

The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice.

Sharmila Shankar1, Thiyam Ramsing Singh, Xufeng Chen, Hitesh Thakkar, Jason Firnin, Rakesh K Srivastava.   

Abstract

TRAIL primarily induces apoptosis in cancer cells but not in normal cells. However, some TRAIL-resistant cancer cell lines have recently been discovered. Ionizing radiation may enhance the apoptosis inducing potential of TRAIL in sensitive cells, and sensitize TRAIL-resistant cancer cells. We assessed the influence of sequential treatment of irradiation followed by TRAIL on intracellular mechanisms of apoptosis of breast tumor cells in vitro and on tumor regression in xenografted athymic nude mice. Irradiation augmented TRAIL-induced apoptosis in breast cancer cells through up-regulation of DR5, and subsequent activation of caspases-3, -8 and -9. Inhibition of p53 by siRNA abrogated irradiation-induced DR5 expression, suggesting the requirement of p53 for DR5 induction. The pretreatment of cells with irradiation followed by TRAIL significantly induced more apoptosis than single agent alone or concurrent treatment with irradiation and TRAIL. The sequential treatment of xenografted mice with irradiation followed by TRAIL-induced apoptosis through caspase-3 activation, completely eradicated the established breast tumors, and enhanced survival of mice without detectable toxicity to normal tissues. The sequential treatment with irradiation followed by TRAIL provides an approach to enhance therapeutic potential of TRAIL. Thus, irradiation can be combined with TRAIL in breast cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067334

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  21 in total

1.  WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis.

Authors:  Sireesha V Garimella; Andrea Rocca; Stanley Lipkowitz
Journal:  Mol Cancer Res       Date:  2011-11-23       Impact factor: 5.852

Review 2.  Combined modality therapy with TRAIL or agonistic death receptor antibodies.

Authors:  Hope M Amm; Patsy G Oliver; Choo Hyung Lee; Yufeng Li; Donald J Buchsbaum
Journal:  Cancer Biol Ther       Date:  2011-03-01       Impact factor: 4.742

3.  Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody.

Authors:  Yang Feng; Xiaodong Xiao; Zhongyu Zhu; Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

4.  Isolation of a TRAIL antagonist from the serum of HIV-infected patients.

Authors:  David J Schnepple; Brett Shepard; Gary D Bren; Nathan W Cummins; Sekar Natesampillai; Sergey Trushin; Alicia Algeciras-Schimnich; Xue W Meng; Amy M Sainski; Stacey A Rizza; Scott H Kaufmann; Andrew D Badley
Journal:  J Biol Chem       Date:  2011-08-22       Impact factor: 5.157

5.  Plumbagin enhances TRAIL-mediated apoptosis through up-regulation of death receptor in human melanoma A375 cells.

Authors:  Jiawen Li; Qin Shen; Rui Peng; Rongyi Chen; Ping Jiang; Yanqiu Li; Li Zhang; Jingjing Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

6.  Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.

Authors:  Ji-Young Jang; Yoon-Kyung Jeon; Yun Choi; Chul-Woo Kim
Journal:  Mol Cancer       Date:  2010-09-28       Impact factor: 27.401

7.  Combined treatment with lexatumumab and irradiation leads to strongly increased long term tumour control under normoxic and hypoxic conditions.

Authors:  Patrizia Marini; Dorothea Junginger; Stefan Stickl; Wilfried Budach; Maximilian Niyazi; Claus Belka
Journal:  Radiat Oncol       Date:  2009-10-27       Impact factor: 3.481

Review 8.  To kill a tumor cell: the potential of proapoptotic receptor agonists.

Authors:  Avi Ashkenazi; Roy S Herbst
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

Review 9.  The TRAIL to targeted therapy of breast cancer.

Authors:  Monzur Rahman; Janet G Pumphrey; Stanley Lipkowitz
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

10.  Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells.

Authors:  Sharmila Shankar; Imtiaz Siddiqui; Rakesh K Srivastava
Journal:  Mol Cell Biochem       Date:  2007-07-17       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.